share_log

Altimmune | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-TIAA-CREF Investment Management, LLC(2.88%),Teachers Advisors, LLC(0.32%), etc.

Altimmune | SC 13G/A：超过5%持股股东披露文件(修正)-TIAA-CREF Investment Management, LLC(2.88%),Teachers Advisors, LLC(0.32%)等

SEC announcement ·  02/14 12:07
Moomoo AI 已提取核心信息
On December 31, 2023, Altimmune Inc., a biopharmaceutical company, was the subject of a Schedule 13G filing with the Securities and Exchange Commission (SEC), indicating changes in ownership by significant investment entities. Nuveen Asset Management, LLC (NAM), TIAA-CREF Investment Management, LLC (TCIM), and Teachers Advisors, LLC (TAL), all based in Delaware, reported their respective holdings in Altimmune's common stock. NAM reported beneficial ownership of 6,679 shares, TCIM reported 1,549,364 shares, and TAL reported 171,273 shares, with all shares being acquired in the ordinary course of business. The combined holdings represent a total of 3.21% of Altimmune's common stock. The filing, dated February 14, 2024, confirms that the shares were not acquired with the intention of changing or influencing the control of Altimmune Inc. The principal executive offices of Altimmune Inc. are located at 910 Clopper Road, Suite 201S, Gaithersburg, MD, United States.
On December 31, 2023, Altimmune Inc., a biopharmaceutical company, was the subject of a Schedule 13G filing with the Securities and Exchange Commission (SEC), indicating changes in ownership by significant investment entities. Nuveen Asset Management, LLC (NAM), TIAA-CREF Investment Management, LLC (TCIM), and Teachers Advisors, LLC (TAL), all based in Delaware, reported their respective holdings in Altimmune's common stock. NAM reported beneficial ownership of 6,679 shares, TCIM reported 1,549,364 shares, and TAL reported 171,273 shares, with all shares being acquired in the ordinary course of business. The combined holdings represent a total of 3.21% of Altimmune's common stock. The filing, dated February 14, 2024, confirms that the shares were not acquired with the intention of changing or influencing the control of Altimmune Inc. The principal executive offices of Altimmune Inc. are located at 910 Clopper Road, Suite 201S, Gaithersburg, MD, United States.
2023年12月31日，生物制药公司Altimmune Inc. 成为向美国证券交易委员会（SEC）提交的附表13G文件的主体，该文件表明重要投资实体的所有权发生了变化。总部位于特拉华州的Nuveen资产管理有限责任公司（NAM）、TIAA-CREF投资管理有限责任公司（TCIM）和Teachers Advisors, LLC（TAL）报告了各自持有的Altimmune普通股。不结盟运动报告了6,679股股票的受益所有权，TCIM报告了1,549,364股股票，TAL报告了171,273股股票，所有股份都是在正常业务过程中收购的。合并持股量共占Altimmune普通股的3.21％。这份日期为2024年2月14日的文件证实，收购这些股票并不是为了改变或影响Altimmune Inc.的控制权。Altimmune Inc.的主要执行办公室位于美国马里兰州盖瑟斯堡克洛珀路910号201S套房。
2023年12月31日，生物制药公司Altimmune Inc. 成为向美国证券交易委员会（SEC）提交的附表13G文件的主体，该文件表明重要投资实体的所有权发生了变化。总部位于特拉华州的Nuveen资产管理有限责任公司（NAM）、TIAA-CREF投资管理有限责任公司（TCIM）和Teachers Advisors, LLC（TAL）报告了各自持有的Altimmune普通股。不结盟运动报告了6,679股股票的受益所有权，TCIM报告了1,549,364股股票，TAL报告了171,273股股票，所有股份都是在正常业务过程中收购的。合并持股量共占Altimmune普通股的3.21％。这份日期为2024年2月14日的文件证实，收购这些股票并不是为了改变或影响Altimmune Inc.的控制权。Altimmune Inc.的主要执行办公室位于美国马里兰州盖瑟斯堡克洛珀路910号201S套房。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息